Syndeio Biosciences Appoints Aaron Koenig, M.D., as Chief Medical Officer (CMO)
Syndeio Biosciences, a clinical-stage biotechnology company focused on therapies to restore and enhance synaptic health in CNS (central nervous system) disorders, appointed Aaron Koenig, M.D., as Chief Medical Officer on November 4, 2025136.
Dr. Koenig has over a decade of experience in neuroscience drug development, clinical care, and translational research, and retains board certification from the American Board of Psychiatry and Neurology1.
His appointment coincides with ongoing Phase 2 trials of Syndeio's lead oral synaptic modulator, zelquistinel, for major depressive disorder and preparations for a synapse biomarker study in Alzheimer’s disease and related dementias15.
Prior to joining Syndeio, Koenig was CMO at Delix Therapeutics (leading neuroplasticity drug portfolios and biomarker studies in depression) and previously held leadership roles at Sage Therapeutics overseeing NMDAR-targeted neuropsychiatry programs1.
Dr. Koenig’s clinical training includes a medical degree from the University of Pennsylvania, psychiatry residency and chief residency at the University of Pittsburgh, geriatric psychiatry fellowship at Penn, and postdoctoral research fellowship at Harvard T.H. Chan School of Public Health1.
Syndeio's synapse pharmacology platform, Boost Platform™, leverages proprietary technology to predict clinical outcomes and de-risk new synaptic agent development, originating from research at Stanford University15.
Sources:
1. https://www.syndeio.bio/news/h3nx6dmiifnnjm54kmqeri2vo4llpz
3. https://www.fundz.net/executives/syndeio-biosciences-hired-84ce
6. https://www.bioworld.com/articles/725805-appointments-and-advancements-for-nov-5-2025